Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine)
Brand Names: Handy Solutions Headache Pain Relief
Methodology & AI Transparency ⓘ
Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a proprietary central nervous system stimulant presentation registered by Navajo Manufacturing Company Inc., Handy Solutions Headache Pain Relief supplies active moiety Acetaminophen, Aspirin, Caffeine (cross-referenced at /meds/acetaminophen-aspirin-caffeine) in 250 mg/1 / 250 mg/1 Tablet; 65 mg/1 / 250 mg/1 Tablet (NDC 67751-215, 82725-1023; SPL 2024-04-15).
- 2 Real-world patient consensus: Registered under RxNorm 308297-B67751215 and SPL 2024-04-15, pairing Handy Solutions Headache Pain Relief packaging with active ingredient Acetaminophen, Aspirin, Caffeine.
- 3 Typical cash cost range: Dispensing cost comparison spans $13.06 mail/discount cash up to $35.06 uninsured retail (federal NADAC $0.0633).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) include headache (8.6%), nausea (8.6%), dizziness (6.2%).
Ask our AI Specialists anything about Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine)
Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) Mechanism, CYP450 Pathways & DailyMed Monograph
As a proprietary central nervous system stimulant presentation registered by Navajo Manufacturing Company Inc., Handy Solutions Headache Pain Relief supplies active moiety Acetaminophen, Aspirin, Caffeine (cross-referenced at /meds/acetaminophen-aspirin-caffeine) in 250 mg/1 / 250 mg/1 Tablet; 65 mg/1 / 250 mg/1 Tablet (NDC 67751-215, 82725-1023; SPL 2024-04-15). Clinical prescribing and dispensing guidelines focus on Uses temporarily relieves minor aches and pains due to ■ headache ■ muscular aches ■ arthritis pain ■ a cold ■ toothache.
The active constituent inside Handy Solutions Headache Pain Relief—Acetaminophen, Aspirin, Caffeine—functions as a targeted central nervous system stimulant agent with class-characteristic hepatorenal disposition. While therapeutic target engagement mirrors generic Acetaminophen, Aspirin, Caffeine, Handy Solutions Headache Pain Relief (registered by Navajo Manufacturing Company Inc., SPL 2024-04-15) specifies proprietary packaging (67751-215, 82725-1023) and 250 mg/1 / 250 mg/1 Tablet; 65 mg/1 / 250 mg/1 Tablet quality controls alongside a $0.0633/unit NADAC acquisition baseline.
Pharmacokinetic profiling of Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) demonstrates an elimination half-life of Terminal t½ estimated at 4–13 hrs depending on renal/hepatic reserve (Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine)) with F ≈ 47%–59% systemic availability after standard oral Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) administration systemic bioavailability; clearance proceeds via mixed metabolic conjugation and unchanged urinary excretion across handy solutions headache pain relief (acetaminophen, aspirin, caffeine) regimens, reaching clinical onset within time to peak concentration spans 1 to 4 hrs under handy solutions headache pain relief (acetaminophen, aspirin, caffeine) maintenance.
Titration schedules for Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) (250 mg/1 / 250 mg/1 Tablet → 65 mg/1 / 250 mg/1 Tablet → 250 mg/1 / 250 mg/1 Tablet, Film Coated → 250 mg/1 / 250 mg/1 Tablet, Coated → 65 mg/1 / 250 mg/1 Tablet, Film Coated) require excluding documented intolerance or hypersensitivity reaction involving acetaminophen, aspirin, caffeine (central nervous system stimulant); concurrent restricted medications flagged in section 4/7 of the handy solutions headache pain relief (acetaminophen, aspirin, caffeine) dailymed monograph (308297-b67751215); real-world patient logs highlight nausea (8.6% of reports), headache (8.6% of reports), dizziness (6.2% of reports) alongside a 90.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) (central nervous system stimulant).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Acetaminophen, Aspirin, Caffeine (central nervous system stimulant)
- Concurrent restricted medications flagged in Section 4/7 of the Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) DailyMed monograph (308297-B67751215)
Logged Side-Effect Incidence (10 Reports)
Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on A randomized, compared against a dummy pill (placebo) trial of 5% and 2%: What a 381-Participant Study Found In this 48-week study of 381 women with female pattern hair loss, 5% applied to the skin minoxidil was superior to placebo on each of the 3 primary efficacy end points: promoting hair growth as measured by change in nonvellus... Journal of the American Academy of Dermatology • 2004-04-15 • Randomized Controlled Trial | N = 381 | 93/100 | PMID 15034503 ↗ |
| New Insights on Benefits and safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in: What a 337-Participant Study Found The real-world benefits and safety of DE-089C administered three times daily at half the dosage of DQS in patients with dry eye were confirmed in this study. Advances in therapy • 2022-08-15 • Phase III Randomized Trial | N = 337 | 93/100 | PMID 35716319 ↗ |
| New Insights on Reversal of Pharmacologically Induced Mydriasis with Phentolamine Ophthalmic: What a 553-Participant Study Found Treatment with POS reduced PD within 60 to 90 minutes, with a statistically significant time savings of 5 to 6 hours to return to baseline PD compared with placebo. Ophthalmology • 2025-01-15 • Phase III Randomized Trial | N = 553 | 93/100 | PMID 39293681 ↗ |
| New Insights on Benefits and safety of clobetasol propionate ophthalmic nanoemulsion for treating: What a 426-Participant Study Found Clobetasol propionate ophthalmic nanoemulsion 0.05% is an effective and safe therapeutic option for treating inflammation and pain associated with cataract surgery. BMJ open • 2026-05-24 • Phase III Randomized Trial | N = 426 | 93/100 | PMID 42192627 ↗ |
| New Insights on Efficacy of a new water-free skin-applied cyclosporine 0.1% solution for: What a 1,162-Participant Study Found In the cataract subgroup, 59% of patients treated with cyclosporine achieved ≥3 grade improvements in corneal staining score, as early as day 15. Journal of cataract and refractive surgery • 2024-06-01 • Phase III Randomized Trial | N = 1,162 | 90/100 | PMID 38334413 ↗ |
Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0633/unit (~$1.90/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $35.06 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $13.06 / mo | View logs ↓ |
| AgelessRx Geroprotective Telehealth (Licensed Telehealth Cash Program) | State-licensed clinician review • ~3d mail fulfillment | $65.00/mo program | Program details |
Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) RxNorm Concept ID | 308297-B67751215 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0633 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $35.06 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $13.06 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 90.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) Patient Community, Cohort Filters & Dosage Logs
Deterministic Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) reference combining NIH RxNorm (308297-B67751215), Medicaid NADAC ($0.0633/unit), and anonymous cohort outcomes (90% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Handy Solutions Headache Pain Relief (Acetaminophen, Aspirin, Caffeine) community threads and patient logs by age, biological sex, dosage, and treatment duration.